View this email in your browser ([link removed])
[link removed]
New Brief: Regulatory Roadblocks Hinder Development of New COVID-19 Treatments for the Immunocompromised
Center for Medical Economics & Innovation | March 6, 2024 | Wayne Winegarden

The current federal regulatory process to develop monoclonal antibodies to treat mutating strains of COVID-19 imposes unnecessary hurdles that hinder the creation and approval of effective treatments for the immunocompromised, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute.

Read here . . . ([link removed])
Sanders Won't Let Facts Get In Way of a Good Pharma Shaming
Newsmax | Sally Pipes | February 29, 2024

The hearing’s official purpose was to discuss prescription drug pricing. But it mainly offered Sanders a forum to castigate the pharmaceutical industry.

“The overwhelming beneficiary of high drug prices in America is the pharmaceutical industry,” Sanders said ([link removed]) . “The United States government does not regulate drug companies. With a few exceptions, the drug companies regulate the United States government.”

Read more... ([link removed])

------------------------------------------------------------

Obamacare coverage might be free. But that's not good.
Austin American-Statesman | Sally Pipes | March 1, 2024

The Biden administration recently announced that a record 21.3 million Americans signed up for Obamacare during this year’s open enrollment period. But many of those enrollees only signed up because they were essentially bribed with free – or nearly free – coverage.

Obamacare coverage may now be free for many low-income Americans. But it’s nothing good.

Read more... ([link removed])

[link removed]

============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Instagram ([link removed])
** Website ([link removed])
Copyright © 2024 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116

** ([link removed])

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.